



Number 63 February 10, 2011

Pharmacy Facts

MassHealth Pharmacy Program

www.mass.gov/masshealth/pharmacy

Editor: Vic Vangel
 Contributors: Chris Burke, Gary Gilmore, Paul Jeffrey, James Monahan, Nancy Schiff

MHDL Update

Below are certain updates to the MassHealth Drug List (MHDL). See the MHDL for a complete listing of updates.

1. Additions

The following newly marketed drugs have been added to the MassHealth Drug List effective February 14, 2011.

Atelvia (risedronate) delayed release – PA Beyaz (drospirenone/ethinyl estradiol/levomefolate) Bromday (bromfenac) – PA Gilenya (fingolimod) – PA Glassia (alpha 1-proteinase inhibitor, human) Kombiglyze XR (saxagliptin/metformin ER) – PA Lo Loestrin Fe (norethindrone/ethinyl estradiol/ ferrous fumarate) Natazia (estradiol valerate and estradiol valerate/ dienogest) Pacnex Cleansing Pads (benzoyl peroxide) – PA Pradaxa (dabigatran) – PA

Silenor (doxepin) – PA

Suboxone (buprenorphine/naloxone) film – PA Suprep Bowel Kit (sodium sulfate/potassium sulfate/magnesium sulfate) – PA Tachosil (fibrinogen/thrombin) patch Tekamlo (aliskiren/amlodipine) – PA

Tobradex ST (tobramycin 0.3%/dexamethasone 0.05%) – **PA** Xeomin (incobotulinum toxinA) – **PA**

2. Change in Prior-Authorization Status

 The prior authorization requirement for the following drug is changing. Please refer to Table 31 and applicable PA request form for PA requirements for this drug.

> Daytrana (methylphenidate transdermal system) – PA < 6 years or > 17 years and PA > 30 units/month

b. The following drugs will no longer require prior authorization.

Aceon # (perindopril) ephedrine injection Sandimmune (cyclosporine) capsules c. The following agent will no longer require prior authorization for \leq 30 units/month.

Wellbutrin XL # (bupropion XL) – PA > 30 units/month

 The following drugs will be restricted to inpatient hospital use effective February 28, 2011.

> Angiomax (bivalirudin) argatroban Refludan (lepirudin)

e. The following ophthalmic antibiotic/ corticosteroid combination drugs will require prior authorization effective February 28, 2011.

> Blephamide (sulfacetamide/prednisolone) – PA
> Poly-Pred (neomycin/polymyxin B/ prednisolone) – PA
> Pred-G (prednisolone/gentamycin) – PA
> Tobradex (tobramycin 0.3%/dexamethasone, ophthalmic ointment 0.1%) – PA
> Zylet (loteprednol/tobramycin) – PA

f. The prior authorization requirements for the following drugs are changing effective February 28, 2011. Please refer to Table 3 and applicable PA request forms for PA requirements for these drugs.

Prilosec # (omeprazole) 10 mg – PA > 30 units/month Prilosec # (omeprazole) 20 mg – PA > 120 units/month Prevacid # (lansoprazole) capsule – PA ≥ 2 years and > 30 units/month

Prevacid SoluTab (lansoprazole, orally disintegrating tablet) – PA ≥ 2 years and > 30 units/month

g. The following drug will require prior authorization effective February 28, 2011.

doxepin 150 mg – PA

h. The following prior authorization requirement for acetaminophen-containing products are effective February 28, 2011.

acetaminophen – PA > 4 grams/day